$XENE News

Last published 1d ago

1d agoXENEGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - XENON PHARMACEUTICALS INCEarnings Call TranscriptsAnd it's my pleasure to introduce our next company, Sinon Pharmaceuticals. From the company, we have Taker Kelly, the CFO, and it's a pleasure to have you here, Taker. So maybe why, before going into the Q&A, you just re
2d agoXENEXenon Reports Q3 2026 Financial Results and Provides Business UpdateGlobeNewswireVANCOUVER, BC and BOSTON, MA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2026 and provided a business update.
2d agoXENEXenon Reports Q3 2026 Financial Results and Provides Business UpdateGlobeNewswireNew Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and
2d agoXENEXenon Pharmaceuticals Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
2d agoXENEQ3 2026 Xenon Pharmaceuticals Inc. Earnings Conference Call - XENON PHARMACEUTICALS INCEarnings Call TranscriptsGood day, everyone, and thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to Xenon Pharmaceutical's third quarter 2026 financial resu
1w agoXENEXenon to Present at Upcoming Investor ConferencesGlobeNewswireVANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
1w agoXENEXenon to Report Q3 2026 Financial Results on November 9, 2026GlobeNewswireVANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
1w agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
1w agoXENEXenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute PainGlobeNewswireXEN1701 achieved target profile, including desired NaV1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effectsXEN1120
3w agoXENEWolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsGlobeNewswireNEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. ("Xenon") common stock (NASDAQ:XENE).
1mo agoXENEWolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsGlobeNewswireNEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. ("Xenon") common stock (NASDAQ:XENE). Xenon is a
1mo agoXENEXENON PHARMACEUTICALS Presenting at TD COWEN 6TH ANNUAL NOVEL MECHANISMS IN NEUROPSYCHIATRY SUMMIT - XENON PHARMACEUTICALS INCEarnings Call TranscriptsHi, everyone, and thank you for joining us at our 2026 TD Cowen Neuropsychiatry Summit. I'm Jotho. I'm one of the senior biotech analysts here on the team at TD Cowan, and it is my pleasure to have with me today two memb
1mo agoXENETD COWEN 6TH ANNUAL NOVEL MECHANISMS IN NEUROPSYCHIATRY SUMMIT - XENON PHARMACEUTICALS INCEarnings Call TranscriptsHi, everyone, and thank you for joining us at our 2026 TD Cowen Neuropsychiatry Summit. I'm Jotho. I'm one of the senior biotech analysts here on the team at TD Cowan, and it is my pleasure to have with me today two memb
1mo agoXENEXenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy SummitGlobeNewswireVANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and
1mo agoXENEAZK NDA Submission and Business Update - XENON PHARMACEUTICALS INCEarnings Call TranscriptsGood day everyone and thank you for standing by. My name is Prilla and I will be your conference operator today. At this time, I would like to welcome everyone to the Xenon Pharmaceuticals conference call. All lines have
1mo agoXENEXenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical ProgramGlobeNewswireNew Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in
2mo agoXENEWells Fargo 21st Annual Healthcare Conference - XENON PHARMACEUTICALS INCEarnings Call TranscriptsOkay, we'll go ahead and get started with the next one. I'm Ben Burnett, biotech analyst at Wells Fargo. Pleased to be here with Tucker Kelly, CFO of Xenon Pharmaceuticals. Tucker, thank you. Great, thanks for having us,
2mo agoXENEWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - XENON PHARMACEUTICALS INCEarnings Call TranscriptsOkay, we'll go ahead and get started with the next one. I'm Ben Burnett, biotech analyst at Wells Fargo. Pleased to be here with Tucker Kelly, CFO of Xenon Pharmaceuticals. Tucker, thank you. Great, thanks for having us,
2mo agoXENEXenon to Present at Wells Fargo Healthcare ConferenceGlobeNewswireVANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and
2mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
2mo agoXENEXenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026GlobeNewswireSix presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety resultsNew poster will highlight the mechanistic characterization of azetukalner, including its potential additive
3mo agoXENEXenon Reports Q2 2026 Financial Results and Provides Business UpdateGlobeNewswireNDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll Three Phase 3 studies of azetukalner in neuropsychiatry
3mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
3mo agoXENEXenon to Report Q2 2026 Financial Results on August 6, 2026GlobeNewswireVANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
4mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
5mo agoXENEJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - XENON PHARMACEUTICALS INCEarnings Call TranscriptsAndrew Tsai, Senior Biotech Analyst, Jefferies, Canada Okay. We're going to get started with our next session. I'm Andrew Tsia, Senior Bio-Tech Analyst here at Jefferies. Thanks for joining. And it's my pleasure to have
5mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
6mo agoXENE2026 GLOBAL HEALTHCARE CONFERENCE - XENON PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everybody. We're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerber. I cover biotech and pharma, and I'm pleased to be introducing Xenon
6mo agoXENEXenon Reports Q1 2026 Financial Results and Provides Business UpdateGlobeNewswireReported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and
6mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development,
6mo agoXENEXenon to Report Q1 2026 Financial Results on May 7, 2026GlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
6mo agoXENEXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingGlobeNewswireAzetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency
7mo agoXENEXenon to Present at Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
7mo agoXENEXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingGlobeNewswireFive abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and
8mo agoXENEXenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
8mo agoXENEXenon Pharmaceuticals Announces Proposed Public OfferingGlobeNewswireVANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical
8mo agoXENEPhase 3 X-TOLE2 Study Topline Results - XENON PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Xenon Pharmaceuticals Phase 3, XL2
8mo agoXENEXenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)GlobeNewswireX-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)X-TOLE2
8mo agoXENEXenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026GlobeNewswireVANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development
8mo agoXENEXenon Reports Q4 and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD
9mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development,
10mo agoXENEXenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare ConferenceGlobeNewswirePhase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications
10mo agoXENEXenon to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireVANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and
11mo agoXENEXenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewswireMonthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to attain and regain
11mo agoXENEXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development,
11mo agoXENEXenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025GlobeNewswireVANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and
11mo agoXENEXenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025GlobeNewswireSeven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight the impact of
1y agoXENEXenon to Present at Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and
1y agoXENEXenon Reports Third Quarter 2025 Financial Results & Business UpdateGlobeNewswire– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1
1y agoXENEXenon to Report Q3 2025 Financial Results on November 3, 2025GlobeNewswireVANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and